Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stopping rules for phase II studies.

N Stallard1, J Whitehead, S Todd

  • 1Medical and Pharmaceutical Statistics Research Unit, The University of Reading, PO Box 240, Earley Gate, Reading, Berkshire, RG6 6FN, UK. n.stallard@reading.ac.uk

British Journal of Clinical Pharmacology
|June 26, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rurality, Deprivation and Ethnicity in New Zealand: Population Distributions and Intersecting Impacts on Mortality.

The Australian journal of rural health·2026
Same author

The multifaceted implications of mental fatigue on women's football players' performance in small-sided games.

Psychology of sport and exercise·2025
Same author

Expanding the all-hazards approach to include extreme cold weather: optimising emergency medical care.

BMJ military health·2025
Same author

Stressors faced by forcibly displaced Ukrainians in England within 6 months of arrival: A qualitative study.

Social science & medicine (1982)·2025
Same author

Oncocytic papillary cystadenoma.

British dental journal·2024
Same author

Experiences of UK and Irish family carers of people with profound and multiple intellectual disabilities during the COVID-19 pandemic.

BMC public health·2023
Same journal

Development of a population pharmacokinetic model using combined paediatric and adult data for four pulmonary arterial hypertension drugs.

British journal of clinical pharmacology·2026
Same journal

Case-malformed signal detection and prioritisation using EUROmediCAT data for pharmacovigilance in pregnancy.

British journal of clinical pharmacology·2026
Same journal

ACEi/ARB in adults older than 85 years after AKI: Beyond single-drug paradigm to phenotype-guided care.

British journal of clinical pharmacology·2026
Same journal

Do consumers and healthcare professionals report the same adverse event differently? A paired analysis of duplicate vaccine safety reports in Norway.

British journal of clinical pharmacology·2026
Same journal

Predicting cognitive function in Alzheimer's clinical trials via amyloid β-protein biomarkers.

British journal of clinical pharmacology·2026
Same journal

Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study.

British journal of clinical pharmacology·2026
See all related articles

This study reviews stopping rules for phase II clinical trials, offering flexible designs for early treatment evaluation. The rules are generally easy to understand and implement for researchers.

Area of Science:

  • Clinical Trials
  • Biostatistics
  • Pharmaceutical Research

Background:

  • Phase II clinical trials are small-scale studies that guide further treatment evaluation.
  • Unlike phase III trials, phase II trials offer more design and analysis flexibility.
  • Stopping rules are crucial for efficiently managing these early-phase studies.

Purpose of the Study:

  • To describe and compare various statistical approaches for stopping rules in phase II clinical trials.
  • To provide an accessible overview of different stopping rule designs.
  • To highlight the flexibility in phase II trial design for treatment evaluation.

Main Methods:

  • Review and comparison of existing statistical methods for designing stopping rules.
  • Focus on approaches suitable for phase II clinical trial settings.

Related Experiment Videos

  • Emphasis on ease of description and implementation of stopping rules.

    • Main Results:

    • A range of statistical approaches for stopping rules in phase II trials are presented.
    • The paper compares different methodologies for designing these rules.
    • Most stopping rules are designed for straightforward implementation.

    Conclusions:

    • Stopping rules in phase II trials allow for flexible and efficient clinical evaluation.
    • Various statistical designs exist, with many being user-friendly.
    • Understanding these rules aids in the progression of experimental treatments.